Don't let NEULAND get Out of Hand !!!
アップデート済
-Annual Revenue rose 26%, in the last year to Rs 1,200 Crores. Its sector's average revenue growth for the last fiscal year was 8.4%.
-Annual Net Profit rose 156.2% in the last year to Rs 163.5 Crores. Its sector's average net profit growth for the last fiscal year was 1.3%
-Price to Earning Ratio is 24.9, lower than its sector PE ratio of 42.6.
-FII/FPI have increased holdings from 18.14% to 20.19% in Jun 2023 qtr.
-Mutual Funds have increased holdings from 0.99% to 1.57% in Jun 2023 qtr.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Their products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands.
-Annual Net Profit rose 156.2% in the last year to Rs 163.5 Crores. Its sector's average net profit growth for the last fiscal year was 1.3%
-Price to Earning Ratio is 24.9, lower than its sector PE ratio of 42.6.
-FII/FPI have increased holdings from 18.14% to 20.19% in Jun 2023 qtr.
-Mutual Funds have increased holdings from 0.99% to 1.57% in Jun 2023 qtr.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Their products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands.
トレード稼働中
ノート
Target 1 and counting - Approx 20% achieved so farノート
Target 2 Achievedトレード終了: 利益確定目標に到達
35% Achieved in about 4-5 Weeks
*DISCLAIMER*
For educational purposes only. Not a recommendation.
Treat StopLoss as your best friend to get you out of troubles.
For educational purposes only. Not a recommendation.
Treat StopLoss as your best friend to get you out of troubles.
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。